Clinical trials: Antipsychotics
Schizophrenia, Healthy
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes.
- Trial name
- NCT05748990
- Testing
- Intranasal insulin
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Delirium
Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium
Background: Delirium is an important problem in critical care. Its prevalence often reaches 75% in intensive care patients. Its occurrence is associated with numerous complications and deleterious consequences such as death…
- Trial name
- Haloquet (NCT01811459)
- Testing
- Quetiapine, Haloperidol
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Intellectual Disability, Developmental Disability
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease.
- Conditions
- Intellectual Disability, Developmental Disability, Obesity
- Trial name
- METIDD (NCT05744479)
- Testing
- Metformin, Lifestyle Intervention
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Schizoaffective Disorder
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00159770
- Testing
- ziprasidone versus olanzapine , risperidone or quetiapine, Panss , CGI-C, UKU-SERS-Pa, Blood tests
- Where
- 43 sites in Denmark, Finland and 2 more
- Volunteers
- 290 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizophreniform
Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment
The goal of our research is to check the levels of D-Serine, Glycine, and other Glutamatergic amino acids, in patients with First Psychotic Episode (FPE).
- Conditions
- Schizophrenia, Schizophreniform, Schizoaffective Disorder, Brief Psychotic Episode
- Trial name
- NCT00789022
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shalvata Mental Health Center
Schizophrenia
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
- Trial name
- NCT02634346
- Testing
- ALK3831, Olanzapine
- Where
- 31 sites in United States, Bulgaria and 2 more
- Volunteers
- 403 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Efficacy of Lu 31-130 in Patients With Schizophrenia
The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to placebo.
- Trial name
- NCT00768326
- Testing
- Zicronapine
- Where
- Germany
- Volunteers
- 280 people
- Sponsor
- H. Lundbeck A/S
Adolescent Depression
Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy
We hypothesize that antipsychotic induced hyperprolactinemia can decrease bone mineral accrual and decrease bone mineral content (BMC) in adolescents on antipsychotic therapy. Specifics Aims 1.
- Trial name
- NCT00399776
- Testing
- Bone Density Test
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Creighton University
Schizophrenia, Negative Symptoms in Schizophrenia
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
This study is a prospective, multicenter, controlled, real world study. Patients will be randomly enrolled into the test group and the control group at a ratio of 1:1 during the screening period.
- Trial name
- NCT05646264
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters.
- Trial name
- NCT05542264
- Testing
- SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder Patients
Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder
The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive…
- Trial name
- NCT01871974
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia
Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism
The study is aimed to assess the severities of hyperprolactinemia caused by antipsychotic drugs and the effects of the duration of hyperprolactinemia on bone metabolism in schizophrenia patients.
- Trial name
- NCT03675750
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Schizophrenia Disorders, Psychotic Disorder
Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial
Schizophrenia is a chronic mental health disorder that affects thoughts, emotions, and behaviors. It includes positive symptoms such as hallucinations and delusions, as well as negative symptoms like reduced motivation, social…
- Trial name
- NCT06838104
- Testing
- Melatonin
- Where
- Pakistan
- Volunteers
- 76 people
- Sponsor
- Lahore General Hospital
Schizophrenia
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
The purpose of this study is to evaluate the long-term treatment efficacy, and safety of risperidone long-acting injection in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01894984
- Testing
- Risperidone, Oral atypical anti-psychotic
- Volunteers
- 640 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Weight Gain
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
Lifestyle intervention and certain medications have been shown to be effective for antipsychotic-induced weight gain, but no controlled studies have compared psychological and pharmacological therapies.
- Trial name
- NCT00451399
- Testing
- metformin, lifestyle intervention
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Central South University
Coma
Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning
Intravenous Lipid Emulsion in Improving Coma Of Antipsychotic drugs Acute Poisoning: A Randomized Controlled Trial in Poison Control Center of Ain Shams University Hospitals
- Trial name
- NCT04807634
- Testing
- Intravenous Lipid Emulsion (Intralipid 20%)
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Amenorrhea
Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients
Antipsychotics such as risperidone could induce amenorrhea in schizophrenic patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic induced amenorrhea in…
- Trial name
- NCT01206153
- Testing
- metformin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Central South University
Schizophrenia, Schizoaffective Disorder
Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders
Schizophrenia (SZ) and schizoaffective (SA) disorders are comprised of several debilitating symptoms. It was suggested that compounds with neuroprotective effects might be useful in the management of SZ/SA symptoms.
- Trial name
- NCT01831986
- Testing
- Pregnenolone and L-Theanine
- Volunteers
- 60 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Schizophrenia
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been…
- Trial name
- NCT01157351
- Testing
- paliperidone, risperidone, haloperidole
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Janssen Scientific Affairs, LLC